Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sight Sciences ( (SGHT) ) is now available.
On March 30, 2026, Sight Sciences announced that the U.S. District Court for the District of Delaware issued a March 27, 2026 order preserving a jury’s verdict that Alcon willfully infringed three of its glaucoma-related patents through sales of the Hydrus Microstent. The court awarded $34 million in past damages, plus supplemental damages, interest and an ongoing 10% royalty on Hydrus revenue through November 10, 2028, although no cash will be collected until appeals are resolved and a final, non-appealable judgment is in place.
The ruling reinforces Sight Sciences’ intellectual property position in interventional glaucoma and is expected to result in a $5.4 million success fee expense payable to its litigation counsel, which the company plans to exclude from non-GAAP operating expenses. However, Alcon’s ex parte reexamination challenges at the U.S. Patent and Trademark Office and any subsequent appeals could undermine Sight Sciences’ ability to collect on the judgment if adverse validity decisions become final before the litigation concludes in the company’s favor.
The most recent analyst rating on (SGHT) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative free cash flow, and shrinking equity) and bearish technicals (price below all key moving averages and negative MACD). The earnings call adds some support via improving execution, cost discipline, and 2026 growth guidance tied to reimbursement progress, but valuation signals are limited due to a negative P/E and no dividend.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences, Inc. is an eyecare technology company that develops and commercializes minimally invasive and non-invasive interventional solutions targeting the underlying causes of prevalent eye diseases. Its portfolio includes the OMNI and OMNI Edge Surgical Systems for minimally invasive glaucoma surgery, the SION Surgical System for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye disease due to meibomian gland disease, with a focus on transforming glaucoma and dry eye care for adult patients.
Average Trading Volume: 321,440
Technical Sentiment Signal: Sell
Current Market Cap: $209.5M
For detailed information about SGHT stock, go to TipRanks’ Stock Analysis page.